Stanford Medicine‘s history in cancer immunotherapy dates back to the 1980s – from researching personalized anticancer antibodies to treating pediatric leukemia with T-cells. More recently, Stanford scientists created a host of tools essential to new immunotherapy treatments. They shed light on T-cells, giving scientists a fresh look at the immune system through single-cell analysis and enable the mapping of regulatory DNA. This technology is being used across our research platform, driving PICI research forward. Crystal Mackall, MD | Director Mark Davis, PhD | Co-Director Ansuman Satpathy, MD, PhD | Co-Director All Investigators Related Research Update Where Cancer-killing T-cells Come From Announcement PICI Young Investigator Retreat 2019 Research Update Predicting Childhood Leukemia Relapse Using Machine Learning Announcement, Our Impact PICI at AACR 2025: Data, Direction, Impact Announcement, Press Release Dr. Ira Mellman Joins PICI as President of Research Announcement, Press Release Dr. Karen E. Knudsen Appointed CEO of PICI From Bench to Fireside From Metastatic Melanoma to Immune Engineering with Antoni Ribas, MD, PhD Announcement, From Bench to Fireside Dr. Elizabeth Mittendorf on breast cancer breakthroughs Announcement, From Bench to Fireside PICI’s From Bench to Fireside Podcast Returns